Higher heat shock factor 1 expression in tumor stroma predicts poor prognosis in esophageal squamous cell carcinoma patients by unknown
Liao et al. J Transl Med  (2015) 13:338 
DOI 10.1186/s12967-015-0703-x
RESEARCH
Higher heat shock factor 1 expression 
in tumor stroma predicts poor prognosis 
in esophageal squamous cell carcinoma 
patients
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Abstract 
Background: Heat shock factor 1 (HSF1) is a powerful, multifaceted modifier of carcinogenesis. However, the clinical 
significance and biologic function of HSF1 in esophageal squamous cell carcinoma (ESCC) remain unknown.
Methods: HSF1 was detected in ESCC cell lines, fibroblast cell lines and ESCC xenograft tumors and human ESCC 
tissues by real-time RT-PCR and western blotting. HSF1 protein expression was analyzed by immunochemistry in 134 
ESCC patients followed by correlation with clinicopathological parameters.
Results: HSF1 expression is weak in fibroblast cell 3T3 and moderate in ESCC cell Eca109, but increasing expression 
of HSF1 was observed in both of 3T3 and Eca109 cells when they interplayed with each other. In Eca109 xenograft 
tumors, both tumor cells and stromal fibroblasts showed stronger expression of HSF1. In ESCC patients, the HSF1 
expression in tumor or in stromal cells was significantly associated with tumor stage, lymph node metastasis and 
clinical stage. Multivariate analysis demonstrated a significant negative correlation between disease-free survival 
(DFS), overall survival (OS) and the HSF1 expression in stromal cells (P < 0.05) but not in tumor cells. Additionally, the 
expression of HSF1 in tumor cells or stromal cells was an independent factor for DFS (P = 0.032 or P = 0.012) and OS 
(P = 0.017 or P = 0.013) in metastatic ESCC patients but not for locoregional ESCC. ESCC patients with low HSF1 in 
both tumor cells and stromal cells had the longest survivals (P < 0.001).
Conclusions: The interaction of tumor cells and stromal fibroblasts increases the expression of HSF1 reciprocally in 
tumor microenvironment. The HSF1 expression in stromal cells was significantly associated with poor prognosis of 
ESCC.
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Background
Esophageal squamous cell carcinoma (ESCC), the major 
histological type of esophageal cancer, is the fourth 
most frequent cause of cancer deaths in China [1, 2]. 
Despite general advances in diagnosis and treatment in 
recent years, ESCC is still disturbing because of the poor 
prognosis [3]. High rates of recurrence and metastasis 
facilitate a high mortality rate in ESCC patients. There-
fore, there is an urgent need to explore valuable prognos-
tic biomarkers for ESCC patients.
Heat shock transcription factor 1 (HSF1) is a major 
transcriptional regulator of the heat-shock response 
(HSR) in eukaryotic cells [4]. HSF1 is evoked in response 
to a variety of cellular stressors by the upregulation of 
Hsp70 protein expression. To protect the proteome 
under diverse physiological stresses, HSF1 governs the 
cellular response to disruptions in protein homeostasis 
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by influencing fundamental cellular processes, such 
as cell-cycle control, protein translation, and glucose 
metabolism [5, 6]. A number of studies have indicated 
that HSF1 plays a critical role in carcinogenesis, tumor 
progression and metastasis by regulating the expression 
of heat shock proteins and other molecular targets [7]. 
Recently, studies have revealed that HSF1 not only drives 
transcription in cancer cells but is also capable of repro-
gramming transcription extensively in cancer-associated 
fibroblasts (CAFs). As a result, the activation of HSF1 in 
CAFs promotes malignancy in adjacent cancer cells [8].
Overexpression of HSF1 was observed in a broad range 
of cancer cell lines and human tumors including colorec-
tal cancer, breast cancer, lung cancer [9], hepatocellular 
carcinoma [10], endometrial carcinoma [11], oral squa-
mous cell carcinoma [12], glioma [13], melanoma [14] 
and multiple myeloma [15]. High levels of HSF1 expres-
sion in tumor tissues has been reported to be associated 
with poor progression in patients with breast cancer [16], 
endometrial carcinoma [11], hepatocellular carcinoma 
[17] and Hodgkin’s lymphoma [18]. In addition, a study 
has demonstrated that high expression of HSF1 in peri-
tumoral tissue but not in hepatocellular carcinoma tis-
sue was associated with poorer survival and shorter time 
to recurrence [17]. Moreover, Scherz-Shouval’s study 
observed increased HSF1 expression in stromal cells but 
not in tumor cells, which is an indispensable prognostic 
marker for breast cancer and lung cancer [8]. However, 
the expression of HSF1 in ESCC and its role in ESCC 
remain unclear.
In the present study, we measured the expression pat-
tern of HSF1 in different cell populations, including 
tumor cells and stromal cells, in the tumor microenviron-
ment of ESCC, and investigated their associations with 
patients’ clinical outcomes, to assess whether HSF1 is a 
valuable prognostic biomarker for ESCC.
Methods
Cell lines
The ESCC cell lines Eca109, Kyse530, Kyse510 and mouse 
embryo fibroblast cell line NIH 3T3 (Chinese Academy 
of Sciences, Shanghai, China) were grown in RPMI 1640 
(Invitrogen, USA) supplemented with 10  % fetal bovine 
serum.
Patients and tissue samples
Eight pairs of ESCC tissue specimens and corresponding 
non-tumorous specimens were obtained from patients 
with ESCC who underwent surgical esophageal tissue 
resection at the Cancer Center of Sun Yat-sen University 
(Guangzhou, People’s Republic of China) during 2012. All 
excised samples were obtained within 1 h after the opera-
tion from tumor tissue and corresponding non-tumorous 
tissue 5–10 cm away from the tumor and were immedi-
ately kept in liquid nitrogen until further analysis.
In addition, paraffin-embedded tumor tissue samples 
were obtained from 134 ESCC patients who underwent 
surgery at Sun Yat-Sen University Cancer Center from 
May of 2000 to December of 2002. None of the patients 
had received anticancer treatment prior to surgery, and 
all of the patients had histologically confirmed primary 
ESCC in this retrospective study. Clinical information 
from 134 ESCC samples was described in detail as shown 
in Table  1. The patients had a median age of 61.5  years 
(range 33–90  years); 108 (80.6  %) were males and 26 
(19.4  %) were females. There were 72 (53.7  %) cases of 
Stage I and II tumors and 62 (46.3 %) cases of Stage III 
and IV tumors based on the International Union against 
Cancer 2002 TNM staging system and WHO classifica-
tion criteria [19].







 Male 108 (80.6)
 Female 26 (19.4)
Degree of differentiation
 G1 42 (31.3)
 G2 57 (42.5)
 G3 35 (26.1)
Tumor (T) status
 T1 9 (6.7)
 T2 39 (29.1)
 T3 81 (60.4)
 T4 5 (3.7)
Lymphoid nodal (N) status
 N0 65 (48.5)
 N1 69 (51.5)
Distant metastasis (M) status
 M0 128 (95.5)
 M1 6 (4.5)
TNM stage
 I 7 (5.2)
 IIa–IIb 65 (48.5)
 III 56 (41.8)
 IV 6 (4.5)
Death
 No 40 (29.9)
 Yes 94 (70.1)
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The follow-up data from the 134 patients in this study 
were available and complete. A total of 94 (70.1  %) 
patients died during the follow-up period. The overall 
survival (OS) was defined as the time interval from the 
date of surgery to the date of cancer-related death or the 
end of follow-up (February, 2012), and the disease-free 
survival (DFS) was defined as the time interval from the 
date of surgery to the date of tumor recurrence or tumor 
metastasis. The diagnostic examinations consisted of 
esophagography, CT, chest X-ray, abdominal ultrasonog-
raphy and bone scan when necessary to detect recur-
rence and/or metastasis.
Prior to the use of all of the clinical materials for inves-
tigation, informed consent from patients and approval 
from the Research Ethics Committee of the Sun Yat-Sen 
University Cancer Center were obtained.
Xenograft tumor
The six- to eight-week-old BALB/c-nude mice were pro-
vided by Guangdong Medical Laboratory Animal Centre 
(Guangdong, China) and housed under specific patho-
gen-free conditions in the Laboratory Animal Center of 
Sun Yat-sen University. This study was approved by the 
ethics committee of Sun Yat-Sen University. The mice 
were inoculated subcutaneously under the right shoulder 
with 2 × 106 Eca109 cells. After growth for 5 or 7 weeks, 
the animals were sacrificed, and the xenograft tumors 
were removed for use.
Real‑time RT‑PCR
Total RNA was extracted from cell lines and ESCC tis-
sues were frozen using the Trizol reagent (Invitrogen, 
USA) according to the manufacturer’s instruction. 
Reverse transcription of total RNA (2  μg) was per-
formed using SuperScript II reverse transcriptase. The 
quantification of target and reference glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) genes was per-
formed in triplicate on a LightCycler® 480 II (Roche, 
Applied Science) using a SYBR green-based assay (Bio-
Rad, USA). The primers used in the real-time RT-PCR 
reaction were as follows: HSF-1 forward 5′-ACCCATG 
CTTCCTGCGTGGC-3′ and reverse 5′- TGCTTCTGC 
CGAAGGCTGGC-3′; and GAPDH, forward 5′-GACT 
CATGACCACAGTCCATGC-3′ and reverse 5′-AGAG 
GCAGGGATGATGTTCTG-3′.
Western blot analysis
Total protein was extracted using a lysis buffer and 
protease inhibitor (Beyotime Biotechnology, China). 
Equivalent protein amounts were denatured in an SDS 
sample buffer, and then were separated by SDS-PAGE 
and transferred onto polyvinylidene difluoride mem-
brane. After being blocked with 5 % non-fat dry milk in 
PBS containing 0.05 % Tween-20, the blotted membranes 
were incubated with anti-human HSF1 antibody (1:300, 
Boster, China) and secondary antibody (1:5000, Boster, 
China) thereafter. GAPDH protein levels were also deter-
mined by using the specific antibody (1:1000, Boster, 
China) as a loading control.
Immunohistochemistry
The paraffin-embedded tissues were sectioned into 
4-μm-thick sections. The sections were dewaxed, rehy-
drated and rinsed. The antigens were retrieved by heat-
ing the tissue sections at 100  °C for 20  min in citrate 
(10  mmol/L, pH 6.0) solution when necessary. The sec-
tions were subsequently immersed in a 3  % hydrogen 
peroxide solution for 10  min to block endogenous per-
oxidase activity and were incubated with the primary 
antibody rabbit anti-human HSF1 (1:40, Boster, China) 
at 4  °C overnight. A negative control was performed 
by replacing the primary antibody with PBS. The sec-
tions were then incubated with a horseradish peroxi-
dase labeled secondary antibody (1:100, Boster, China) 
at room temperature for 120 min. Finally, the signal was 
developed for visualization with 3, 3′-diaminobenzidine 
tetrahydrochloride, and all of the slides were counter-
stained with hematoxylin.
Evaluation of immunohistochemical staining
Two independent observers (Yue-Hua Liao and Xin-
Wei Feng) blinded to the clinicopathological informa-
tion scored the HSF1 expression level in tumor cells and 
stromal cells by assessing (a) the proportion of positively 
stained cells (0, <5 %; 1, 6–25 %; 2, 26–50 %; 3, 51–75 %; 4, 
>75 %) and (b) the intensity of staining (0, negative stain-
ing; 1, only cytoplasm staining; 2, low nucleus staining; 
3, strong nucleus staining). The score was the product of 
a × b. The patients were divided into subgroups: a high-
level group (a × b ≥ 7 score in tumor cells; or a × b ≥ 6.5 
score in stromal cells) and a low-level group (a × b < 7 
score in tumor cells; or a × b < 6.5 score in stromal cells) 
based on the medians of immunohistochemical variable 
values in diverse cell subsets in our data.
Statistical analysis
All analyses were conducted with SPSS 16.0 (SPSS Inc., 
Chicago, IL, USA). Pearson’s Chi-square test and Fish-
er’s Chi-square test were used to analyze the correlation 
between HSF1 expression in different cell subsets and the 
patients’ clinicopathological parameters. HSF1 expres-
sion level was examined in tumor cells and in stromal 
cells in relation to the patients’ clinical prognosis using 
the Kaplan–Meier method and the log-rank survival 
analysis. Prognostic factors were assessed by univari-
ate and multivariate analyses using the Cox proportional 
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hazards model. The correlations among the expression 
levels of HSF1 in tumor cells and in stromal cells were 
determined using Pearson’s correlation coefficient and 
linear regression analyses. A two-tailed P value <0.05 was 
considered to be statistically significant in this study.
Results
HSF1 expression in ESCC and fibroblast cell lines
Western blotting and real-time PCR analysis showed that 
both HSF1 mRNA and protein were expressed differ-
ently in three ESCC cell lines: moderately in Eca109 and 
strongly in Kyse 510 and Kyse 530 (Fig. 1a, b). Figure 1c 
showed that HSF1 was less expressed in mice fibroblast 
cell lines 3T3 by western blotting analysis, compared with 
the HSF1 expression of Eca109 cell lines and Kyse510 
cell lines. Eca109 and 3T3 cells were cultured with con-
ditioned medium of each other reciprocally, and the two 
cells cultured under hypoxia stress were used as positive 
control. The same way was used between Kyse510 cells 
and 3T3 cells. As shown in Fig. 1c, increasing expression 
of HSF1 was detected in all of these three cells by west-
ern blotting. In Fig. 1d, the immunohistochemical results 
showed the difference between the Eca109 cells and 3T3 
cells when they were cultured with conditioned medium 
or not.
HSF1 expression in human ESCC xenograft
Then, Eca109 cells were inoculated in nude mice to inves-
tigate the exact interaction state of HSF1 in  vivo. As 
shown in Fig.  2, the human Eca109 recruited the mice 
stromal cells into xenograft tumor masses. Eca109 cancer 
cell nests were surrounded by activated mice fibroblast 
cells, which were fibroblast activation protein-α (FAPα)-
positive by immunohistochemistry (Fig.  2a, b). HSF1 
was present in the nucleus mainly in Eca109 tumor cells, 
and present in the nucleus or distributed between the 
cytoplasm and a diffuse nuclear localization in stromal 
fibroblasts (Fig. 2c, d). Both Eca109 tumor cells and the 
mice stromal fibroblasts showed strong HSF1 positivity 
in in vivo tumor xenografts. These results indicated that 
these two cell lines, fibroblast cells and esophageal carci-
noma cells, interplay with each other in the tumor micro-
environment, which leads to the increasing expression of 
HSF1 reciprocally.
HSF1 expression in human normal and ESCC tissues
To investigate the expression of HSF1 in human ESCC 
tissues, we examined the expression of HSF1 in tumor 
tissues and matched normal adjacent tissues from eight 
ESCC patients by western blotting and real-time PCR 
analysis. As shown in Fig.  3a, in seven of eight cases, 
Fig. 1 Expression of HSF1 in esophageal squamous cells and fibroblasts. a HSF1 protein expression was detected by western blot and b HSF1 
mRNA expression was detected by qPCR in the ESCC cell lines Eca109, Kyse 510, Kyse 530. c HSF1 expression of Eca109 cultured with 3T3-condi-
tioned culture, 3T3 cultured with Eca109-conditioned culture and Kyse510 cultured with 3T3-conditioned culture were detected by western blot. d 
HSF1 expression of Eca109 cultured with 3T3-conditioned culture and 3T3 cultured with Eca109-conditioned culture were detected by immunohis-
tochemical staining (×200)
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more HSF1 was present in the tumors than in the 
matched controls’ adjacent tissue. The expression of 
HSF1 in tumor was the same as the expression in normal 
tissue in only one case. Consistent with the upregulated 
protein level, HSF1 mRNA expression was also upregu-
lated in tumor tissue compared with the paired non-
tumor tissue as analyzed by real-time PCR (Fig. 3b). The 
tumor/normal (T/N) ratio of HSF1 message signals var-
ied from approximately 1.0- to 15.6-fold in eight paired 
tissues.
Expression of HSF1 in ESCC and its correlations 
with clinicopathological parameters
To investigate the correlations of HSF1 expression and 
clinicopathological parameters, the level of HSF1 pro-
tein was next determined by immunohistochemistry in 
134 archival ESCC tissues. HSF1 protein was detected 
in 124 of 134 ESCC cases (92.54 %), including 128 cases 
(95.52 %) in cancer cell nests and 124 cases (92.54 %) in 
cancer stroma. HSF1 immunoreactivity was observed 
at various levels, and localization was observed in the 
nucleus and cytoplasm of both tumor cells (Fig.  4) and 
stromal cells (Fig.  5). Based on the criteria described in 
the methods section, a high expression level of HSF1 in 
tumor cells was noted in samples from 74 (55.2 %) of the 
134 patients. As in tumor cells, a high expression level of 
HSF1 in stromal cells was also found in samples from 74 
(55.2 %) of the 134 patients.
Fig. 2 Expression of HSF1 in human Eca109 xenograft tumors. The FAPα staining (a ×100; b ×400) and HSF1 staining (c ×100; d ×400) in human 
Eca109 xenograft tumors
Fig. 3 Expression of HSF1 in ESCC carcinoma tissue and matched 
normal adjacent tissue. a HSF1 protein expression was detected by 
western blot and b HSF1 mRNA expression was detected by qPCR in 
ESCC tumors and normal tissues from four 8 ESCC patients
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The associations between clinicopathological features 
and HSF1 expression in tumor cells and stromal cells 
in samples from 134 ESCC patients were summarized 
in Table 2. High expression level of HSF1 in tumor cells 
were closely associated with advanced clinicopathologi-
cal characteristics, including tumor (T) status (P < 0.001), 
node (N) status (P = 0.017) and clinical stage (P = 0.007), 
but not significantly associated with age, gender, degree 
of differentiation and distant metastasis (M) status. Fur-
thermore, the expression level of HSF1 in stromal cells 
was not only related to the clinicopathological parame-
ters, including T status (P < 0.001), N status (P = 0.002) 
and clinical stage (P  =  0.007), but also related to the 
gender (P  =  0.019) and the degree of differentiation 
(P = 0.035). There was no significant correlation between 
the expression level of HSF-1 protein in stromal cells 
with age and M status.
Expression level of HSF1 in tumor cells and stromal cells 
and ESCC patient survival
Among the 134 patients with ESCC, the median sur-
vival time was 25  months (range 0–133  months). The 
cumulative 5-year OS rate and DFS rate of the patients 
in this study were 32.8 and 28.8  %, respectively. Fur-
thermore, the cumulative ten-year OS rate and DFS 
rate of the patients in this study were 22.3 and 22.0  %, 
Fig. 4 Immunohistochemical staining for HSF1 in tumor cells of ESCC. The negative expression level (a ×100; b ×400), low expression level 
(c ×100; d ×400) and high expression level (e ×100; f ×400) of HSF1 in tumor tissues from patients with ESCC
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respectively. Figure  6a,b shows a significant negative 
correlation between the HSF1 expression in tumor cells 
and DFS (P = 0.001) and OS (P = 0.003). Likewise, there 
was a significant negative correlation between the HSF1 
expression in stromal cells and DFS (P < 0.001) and OS 
(P < 0.001) (Fig. 6c, d).
The multivariate analysis demonstrated that except 
for certain conventional clinicopathological parameters, 
such as gender and nodal status, the HSF1 in stromal 
cells but not in tumor cells was an independent unfa-
vorable factor for DFS (P =  0.019) and OS (P =  0.017) 
(Table 3).
Among the 134 patients with ESCC, there were 65 
(48.5  %) patients with locoregional ESCC and 69 cases 
(51.5  %) with metastatic ESCC. The Kaplan–Meier sur-
vival analysis showed that the high expression of HSF1 
in tumor cells or the high expression of HSF1 in stro-
mal cells was significantly correlated with poor OS 
(P = 0.017, P = 0.013) and DFS (P = 0.032, P = 0.012) 
in patients with metastatic ESCC (Fig. 7b) but not corre-
lated with poor OS and DFS in patients with locoregional 
ESCC (Fig. 7a). The results suggested that the expression 
of HSF1 may be a potential prognostic marker for meta-
static ESCC, but not locoregional ESCC.
Fig. 5 Immunohistochemical staining for HSF1 in stromal cells of ESCC. The negative expression level (a ×100; b ×400), low expression level 
(c ×100; d ×400) and high expression level (e ×100; f ×400) of HSF1 in tumor stroma from patients with ESCC
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The combined expression levels of HSF1 in both tumor 
cells and stromal cells and the survival of ESCC patients
In the current study, Pearson’s correlation coefficient 
and a linear regression analysis were applied to analyze 
the correlation between the expression levels of HSF1 
in tumor cells and in stromal cells. The HSF1 expres-
sion level in tumor cells was positively associated with 
the HSF1 expression level in stromal cells (P  <  0.001, 
R = 0.706; Fig. 8a). Figure 8b, c showed that the patients 
with a combined low expression level of HSF1 both in 
tumor cells and stromal cells had the longest DFS and OS, 
related to those with a single high expression level only in 
tumor cells or in stromal cells or with a combined high 
expression level both in tumor cells and in stromal cells. 
Additionally, the patients with a single high expression 
level of HSF1 only in stromal cells had the shortest DFS 
and OS, which indicated that the high expression level of 
HSF1 in stromal cells is more likely to be the marker for 
prognosis rather than the high expression level of HSF1 
in tumor cells.
Discussion
In this study, we revealed that the expression of HSF1 was 
increased in both fibroblast cells and ESCC cells by the 
interaction in the tumor microenvironment. This finding 
indicated that the tumor cells and fibroblasts can induce 
each other reciprocally in HSF1 expression to facilitate 
tumor progression and metastasis.
Furthermore, we revealed that HSF1 is located in the 
nucleus and cytoplasm of both tumor cells and stromal 
cells close to malignant cells in the human ESCC tissues. 
Strong staining of HSF1 in the nucleus was significantly 
associated with both advance stage ESCC and poor prog-
nosis in ESCC. Our data were in line with other studies 
in which high levels of HSF1 expression in the nucleus of 
several types of cancer, such as breast cancer [16], mela-
noma and hepatocellular carcinoma, [17] was associated 
with reduced survival.
HSF1 has historically been viewed as a stress-activated 
transcription factor. Under basal conditions in normal 
cells, HSF1 resides primarily in the cytoplasm. Upon 
activation, it accumulates in the nucleus. In tumors, 
the high level of HSF1 in the nucleus is a master regu-
lator of protein homeostasis and cell survival to cope 
with a variety of potentially lethal challenges [20]. It has 
also been determined that the HSF1 program supports 
the malignancy of cancer in a variety of ways, includ-
ing direct effects on the cell cycle, DNA repair, anabolic 
Table 2 Clinicpathological associations of HSF-1 expression levels in 134 patients with ESCC
* P < 0.05, as determined by Pearson’s Χ2 test
Clinicopathologic parameter Total case  
(n = 134)
High level of HSF‑1  
in tumor (%)




 ≤61 67 37 (55.2) 0.727 36 (53.7) 0.486
 >61 67 39 (58.2) 40 (59.7)
Gender
 Female 26 11 (42.3) 0.099 10 (38.5) 0.036*
 Male 108 65 (60.2) 66 (61.1)
Degree of differentiation
 G1 42 18 (42.9) 0.082 17 (40.5) 0.021*
 G2 57 37 (64.9) 39 (68.4)
 G3 35 21 (60.0) 20 (57.1)
T status
 T1–2 48 15 (31.2) <0.001* 15 (31.2) <0.001*
 T3–4 86 61 (70.9) 61 (70.9)
N status
 N0 65 29 (44.6) 0.006* 28 (43.1) 0.002*
 N1 69 47 (68.1) 48 (69.6)
M status
 M0 128 73 (57.0) 1.000 72 (56.2) 0.935
 M1 6 3 (50.0) 4 (66.7)
Clinical stage
 I–II 72 32 (44.4) 0.002* 33 (45.8) 0.006*
 III–IV 62 44 (71.0) 43 (69.4)
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metabolism, and proliferation [21]. The overexpression of 
HSF1 in the nucleus of tumor cells indirectly promotes 
tumorigenesis by enabling proliferation, invasion and 
metastasis [22, 23]. HSF1 may also play these roles in 
ESCC and thus account for high levels of HSF1 expres-
sion in the nucleus of ESCC tumor cells associated with 
patients’ poor outcomes.
HSF1 expression was not only found in the ESCC 
tumor cells but also in stromal cells, primarily close 
to tumor cells in the microenvironment of ESCC tis-
sues. The increased level of HSF1 in the stromal cells 
was significantly associated with the clinicopathologic 
parameters. High levels of HSF1 in stromal cells were 
correlated strongly with shorter survival in patients 
with ESCC. These results suggest that the high expres-
sion of HSF1 in both tumor cells and stromal cells may 
be associated with the prognosis of ESCC. Recently, 
Scherz-Shouval et  al. described that overexpression of 
HSF1 in the CAFs promotes malignancy in adjacent 
cancer cells. HSF1 activation in the stromal cells corre-
lated strongly with poor outcome in both lung and breast 
cancer [21]. Zhang JB et al. reported that hepatocellular 
carcinoma patients with high expression of peritumoral 
HSF1, but not intratumoral HSF1, have a poor survival, 
even in patients with slight hepatocellular carcinoma or 
low α-fetoprotein level. Stromal cells within the tumor 
microenvironment are essential for tumor progression 
and metastasis [17]. It is well-known that the cells of the 
tumor microenvironment contribute to the hallmarks of 
cancer, and their interaction with cancer cells plays an 
important role in tumor formation and progression [24, 
25]. The microenvironment can provide crucial signal-
ing to maintain tissue architecture, such as the HSR [26]. 
However, the microenvironment can also promote and 
induce cancer [27]. If the HSR is governed by the tumor, 
it may be changed to support cancer cell formation and 
progression. It is known that HSF1 activation is a key fac-
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Fig. 6 Kaplan-Meier survival analysis in patients with ESCC. a, b Overall survival and disease-free survival curves for patients according to the low 
and high expression levels of HSF1 in tumor cells. c, d Overall survival and disease-free survival curves for patients according to the low and high 
expression level of HSF1 in stromal cells
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from a tumor-repressive environment to a supportive 
one by upregulating genes that promote the malignant 
phenotype and by downregulating genes that might trig-
ger an anticancer immune response. HSF1 might involve 
in ESCC microenvironment through the same molecu-
lar mechanism. Our dates revealed that only the high 
expression of HSF1 in stromal cells was related to poor 
prognosis, rather than the expression of HSF1 in nucleus 
in tumor cells, which demonstrated that the HSF1 acti-
vation in stromal cells was a key factor in the malignant 
elements. Furthermore, multivariate Cox model analysis 
showed that only HSF1 expression in stromal cells but 
not in tumor cells was an independent prognostic marker 
for ESCC.
Additionally, we observed that high expression of 
HSF1, whether in tumor cells or in stromal cells, was an 
independent predictor of DFS and OS in patients with 
metastatic ESCC, but not locoregional ESCC. This result 
showed that the HSF1 activation is a more predictive 
prognostic marker for metastatic ESCC, which means 
that HSF1 may play a more significant role in tumor 
migration.
Consistent with these results, in early stage non-small-
cell lung cancer and liver cancer patients, HSF1 activa-
tion in stromal cells has a more important effect on the 
progression of these patients than its activation in tumor 
cells. Why does the expression of HSF1 in tumor cells and 
in stromal cells show different associations with ESCC? 
It has been determined out that stromal HSF1 activa-
tion drives specific beneficial pathways to the malignant 
elements, facilitating angiogenesis, ECM organization, 
adhesion, and migration [20]. HSF1 activation in stromal 
cells plays a more significant role in the tumor progres-
sion or migration and thus may be a better predictor for 
ESCC patients’ prognosis. In this study, the level of HSF1 
expression in tumor cells was positively associated with 
the HSF1 level in stromal cells. ESCC patients with a 
combined low expression level of HSF1 both in tumor 
cells and stromal cells had the longest DFS and OS, 
whereas the patients with a single high expression level of 
Table 3 Multivariate cox regression analysis for OS of 134 patients with ESCC
* P < 0.05
Variables OS DFS
HR (95 % CI) P HR (95 % CI) P
HSF-1 expression in tumor cells (n = 134)
 Gender (male/female) 0.352 (0.177–0.700) 0.003* 0.401 (0.203–0.792) 0.009*
 Age (≤61/>61) 0.838 (0.546–1.286) 0.419 0.956 (0.607–1.506) 0.846
 Degree of differentiation (1/2/3) 1.195 (0.902–1.585) 0.215 1.199 (0.904–1.592) 0.208
 Tumor (T) status (1–2/3–4) 0.879 (0.449–1.720) 0.706 0.880 (0.447–1.732) 0.712
 Nodal (N) status (0/1) 2.977 (1.464–6.055) 0.003* 2.823 (1.376–5.791) 0.005*
 Metastasis (M) status (0/1) 1.350 (0.448–4.066) 0.594 1.392 (0.464–4.179) 0.555
 Clinical status (I II/III IV) 0.805 (0.520–1.247) 0.330 0.845 (0.541–1.322) 0.461
 HSF1 in tumor cell (low/high) 1.465 (0.916–2.341) 0.111 1.491 (0.928–2.396) 0.099
HSF1 expression in stromal cells (n = 134)
 Gender (male/female) 0.351 (0.177–0.696) 0.003* 0.411 (0.208–0.810) 0.010*
 Age (≤61/>61) 0.788 (0.511–1.215) 0.281 0.887 (0.562–1.399) 0.605
 Degree of differentiation (1/2/3) 1.143 (0.862–1.514) 0.354 1.157 (0.871–1.536) 0.314
 Tumor (T) status (1–2/3–4) 0.724 (0.363–1.441) 0.358 0.736 (0.368–1.472) 0.386
 Nodal (N) status (0/1) 2.490 (1.201–5.162) 0.014* 2.330 (1.104–4.918) 0.026*
 Metastasis (M) status (0/1) 1.032 (0.334–3.190) 0.956 1.108 (0.364–3.372) 0.856
 Clinical status (I II/III IV) 0.904 (0.577–1.414) 0.658 0.959 (0.604–1.523) 0.859
 HSF1 in stromal cell (low/high) 2.039 (1.243–3.345) 0.005* 2.000 (1.208–3.311) 0.007*
HSF1 expression in N0 (n = 65)
 Gender (male/female) 0.151 (0.039–0.586) 0.006* 0.199 (0.058–0.680) 0.010*
 Degree of differentiation (1/2/3) 1.666 (0.993–2.797) 0.053 1.691 (1.028–2.782) 0.039*
 HSF1 in tumor cell (low/high) 0.493 (0.126–1.931) 0.310 0.452 (0.110–1.867) 0.273
 HSF1 in stromal cell (low/high) 2.935 (0.634–13.591) 0.168 3.115 (0.712–13.624) 0.131
HSF1 expression in N1 (n = 69)
 HSF1 in tumor cell (low/high) 0.657 (0.235–1.833) 0.422 0.809 (0.292–2.245) 0.684
 HSF1 in stromal cell (low/high) 3.038 (1.055–8.753) 0.040* 2.617 (0.893–7.665) 0.079
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P=0.012
b
Fig. 7 Kaplan-Meier survival analysis in patients with locoregional ESCC and metastatic ESCC. a Overall survival and disease-free survival curves for 
patients with low and high expression levels of HSF1 in locoregional ESCC. b Overall survival and disease-free survival curves for patients with low 
and high expression levels of HSF1 in metastatic ESCC
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HSF1 in stromal cells had the shortest DFS and OS, sug-
gesting that the levels of HSF1 activation both in tumor 
cells and stromal cells and, especially, in stromal cells 
could improve the ability to predict patient outcome. 
HSF1 drives a transcriptional program in stromal cells 
that complements but is completely different from the 
program it drives in adjacent cancer cells. This stromal 
cell program driven by HSF1 is uniquely structured to 
support malignancy in a non-cell-autonomous way. The 
cooperation between HSF1 activation in stromal cells 
and tumor cells may promote tumor development. Thus, 
this cooperation may account for the better outcome of 
ESCC patients with low levels of HSF1 activation both in 
stromal cells and tumor cells.
Conclusions
Our data reveal that the increasing expression of HSF1 
is found in ESCC tumor cells and stromal cells recipro-
cally when they interplay with each other in the tumor 
microenvironment. Furthermore, the high level of HSF1 
expression in both tumor cells and stromal cells was sig-
nificantly associated with worse DFS and OS of ESCC 
patients. High HSF1 expression in stromal cells was a 
better predictor for ESCC patients’ prognosis than its 
HSF-1 high expression both in tumor cells and stromal cells
HSF-1 high expression only in stromal cells
HSF-1 high expression only in tumor cells
































































Fig. 8 Correlation of HSF1 in diverse cell populations and survival analysis in diverse cell populations. a The expression level of HSF1 in tumor 
cells and stromal cells were significantly positively correlated (P < 0.001, R = 0.668). b Overall survival and disease-free survival curves for patients 
according to the combined low expression level and combined high expression level of HSF1 in tumor cells and stromal cells, and the single high 
expression level in tumor cells or in stromal cells
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expression in tumor cells, especially in patients with met-
astatic ESCC. Low levels of HSF1 activation both in stro-
mal and tumor cells predict the best outcome for ESCC 
patients, suggesting that HSF1 activation is a potential 
biomarker for ESCC patient prognosis. These findings 
suggest the possibility of treating ESCC cancer by iden-
tifying drugs to targeting HSF1 functions both in the 
malignant cells and the more genetically stable stroma.
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